SecBot SecBot
PRESS-RELEASE ·Filed Mar 16, 2026

CTMX

CytomX Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor upcoming FDA interactions on Varseta-M registrational pathway and clinical data readouts in 2026, particularly the CX-801/KEYTRUDA® combination data. While pipeline progress offers upside potential, the sharp revenue decline and reliance on future milestones increase risk; any delay could pressure valuation despite strong cash position.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.75
T+0 close · Mar 16, 2026 · via day close
Latest settled
−56.44%
T+60 · $2.94
Vs SPY
−66.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $6.75entry
  2. T+1 · 8mo ago −19.26%α −19.53% · $5.45
  3. T+5 · 8mo ago −33.93%α −31.88% · $4.46
  4. T+20 · 7mo ago −32.74%α −36.52% · $4.54
  5. T+60 · 5mo ago −56.44%α −66.93% · $2.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue decline to $76.2 million from $138.1 million in 2024, driven by the completion of collaboration milestones. However, the company announced positive Phase 1 data for its Varseta-M ADC in colorectal cancer and extended its cash runway into Q2 2027. Despite advancing its pipeline, including upcoming combination data for CX-801 with KEYTRUDA®, the sharp drop in revenue and net loss of $17.4 million weigh on near-term fundamentals.

Key Financial Metrics

Revenue
$76.2M
-44.8% YoY
EPS
$-0.15

Key Facts

  • Revenue dropped to $76.2 million in 2025 from $138.1 million in 2024, primarily due to completion of performance obligations with Bristol Myers Squibb and reduced collaboration progress with Moderna, Astellas, and Regeneron.
  • Net loss was $17.37 million in 2025 compared to net income of $31.87 million in 2024.
  • Cash, cash equivalents, and investments totaled $137.1 million as of December 31, 2025, providing a cash runway into Q2 2027.
  • Positive Phase 1 dose expansion data reported for Varseta-M in advanced colorectal cancer; FDA interactions planned for mid-2026 to align on registrational trial design.
  • Phase 1 combination study of CX-801 with KEYTRUDA® in melanoma ongoing, with initial clinical data expected by end of 2026.
  • Astellas terminated its preclinical collaboration with CytomX, effective Q2 2026.

Financial Impact

Revenue declined by 44.8% year-over-year, from $138.1M to $76.2M. Operating expenses decreased to $98.6M from $113.1M, but the company still posted a net loss of $17.37M. Cash balance increased to $137.1M due to prior funding and lower R&D spend.

revenuenet incomecash runwayR&D expense

Risk Factors

  • Heavy dependence on clinical success of Varseta-M and CX-801 with no near-term commercial revenue.
  • Revenue is largely collaboration-dependent and declined significantly after key milestones were completed.
  • Forward-looking statements dominate the release; clinical timelines and regulatory alignment are uncertain.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3256146

Track record

10 reports on CTMX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $1.98 Now $1.99 +0.25% settles Feb 8
  2. Nov 5, 202611d ago Press Release Bearish 5/10 No price data
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.19 Now $1.99 −9.36% settles Feb 4
  4. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $2.36 Now $1.99 −15.89% settles Jan 26
  5. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $2.94 Now $1.99 −32.48% settles Dec 16
  6. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $3.15 to $2.77 Now $1.99 −36.98% ▼ −12.22% −15.47% vs SPY
  7. Mar 17, 202634w ago Press Release Neutral 6/10 Entry $4.40 to $2.98 Now $1.99 −54.89% ▼ −32.27% −43.80% vs SPY
  8. Mar 16, 202635w ago Press Release Bearish 7/10 Entry $5.45 to $2.98 Now $1.99 +63.58% ▲ +45.32% +55.18% vs SPY
  9. Mar 16, 202635w ago Press Release Mixed 6/10 Viewing Entry $6.75 to $2.94 Now $1.99 −70.59% ▼ −56.44% −66.93% vs SPY
  10. Mar 4, 202636w ago Press Release Neutral 3/10 Entry $5.07 to $3.71 Now $1.99 −60.85% ▼ −26.82% −36.91% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 16, 2026